about
Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model.Cost-effectiveness analysis of the analgesic therapy of postoperative pain.Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis.Budget impact and cost-effectiveness: can we afford precision medicine in oncology?The use of mechanistic evidence in drug approval
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Evaluation and review of pharmacoeconomic models.
@ast
Evaluation and review of pharmacoeconomic models.
@en
type
label
Evaluation and review of pharmacoeconomic models.
@ast
Evaluation and review of pharmacoeconomic models.
@en
prefLabel
Evaluation and review of pharmacoeconomic models.
@ast
Evaluation and review of pharmacoeconomic models.
@en
P2860
P1476
Evaluation and review of pharmacoeconomic models.
@en
P2093
Joel W Hay
P2860
P304
P356
10.1517/14656566.5.9.1867
P407
P577
2004-09-01T00:00:00Z